SURMOUNT-5: Tirzepatide Beat Semaglutide — What It Means

For years, the question that patients, clinicians, and payers all wanted answered was: if you had to choose between semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), which one works better? Indirect comparisons across separate trials were always limited by differences in populations, designs, and follow-up periods. SURMOUNT-5 finally gave us the head-to-head data. The results — published in The New England Journal of Medicine in early 2025 — showed that tirzepatide significantly outperformed semaglutide on the primary weight loss outcome. But understanding what those results actually mean for individual patients, particularly those with gut health concerns, requires going beyond the headline number.

SURMOUNT-5: Trial Design and What Made It Rigorous

SURMOUNT-5 was a Phase 3b, randomized, open-label, active-controlled trial that enrolled 751 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. Participants were randomized to tirzepatide (target dose 10mg or 15mg weekly) or semaglutide 2.4mg weekly, the approved weight management dose of Wegovy. The trial ran for 72 weeks, which is long enough to capture meaningful weight loss plateau data. Randomization, baseline characteristics, and outcome assessment were rigorously conducted, making this the most credible head-to-head comparison between the two leading GLP-1 class medications available to date.

The open-label design — patients knew which drug they were taking — is a common criticism, but it is largely unavoidable in drug comparison trials where injection appearance, device design, and dosing frequency differ between the two agents. The trial used validated, objective outcome measures (dual-energy X-ray absorptiometry for body composition, standardized waist circumference measurements) alongside the primary endpoint of percent body weight change. Importantly, intention-to-treat analysis was the primary analysis, and sensitivity analyses for missing data and dropout were pre-specified, adding robustness to the results.

The Results: 47.2% vs 33.9% — What Those Numbers Mean

The headline result of SURMOUNT-5 was that 47.2% of tirzepatide participants achieved ≥15% body weight loss at 72 weeks, compared to 33.9% of semaglutide participants — a difference of approximately 13 percentage points that was highly statistically significant. Mean percent weight loss was 20.2% in the tirzepatide arm versus 13.7% in the semaglutide arm, a 6.5 percentage point difference in absolute terms. To put these numbers in clinical context: for a 250-pound person, the mean difference between the two drugs represents approximately 16 additional pounds lost over 72 weeks.

At higher weight loss thresholds, the separation was even more pronounced. Achieving ≥20% body weight loss — a threshold associated with particularly significant metabolic improvements — occurred in 31.6% of tirzepatide participants versus 16.1% of semaglutide participants. The ≥25% weight loss threshold was achieved by 19.4% of tirzepatide patients but only 7.2% of semaglutide patients. These differences reflect tirzepatide's dual agonism at both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which appears to produce additive or even synergistic effects on appetite suppression, energy expenditure, and fat oxidation compared to GLP-1 agonism alone.

GI Side Effect Comparison: The Gut Health Picture

For patients with gut health concerns, the side effect data from SURMOUNT-5 is as important as the efficacy data. Overall GI adverse event rates were similar between the two drugs — approximately 73% of tirzepatide participants and 71% of semaglutide participants reported at least one GI adverse event during the trial. Nausea was reported in 42% of tirzepatide vs 47% of semaglutide participants — slightly lower for tirzepatide despite its greater potency, potentially because tirzepatide's GIP receptor component modulates nausea pathways. Vomiting rates were 23% (tirzepatide) vs 26% (semaglutide). Diarrhea was 30% vs 22%, with tirzepatide producing slightly more diarrhea.

Constipation rates were 21% for tirzepatide and 19% for semaglutide — both clinically significant. Serious GI adverse events (requiring hospitalization or resulting in drug discontinuation) occurred in approximately 5% of participants in each arm, a similar rate. The slightly higher diarrhea rate with tirzepatide compared to semaglutide is consistent with GIP receptor activation having independent effects on intestinal motility that differ from pure GLP-1 receptor activation. For patients with IBS-D (diarrhea-predominant), this distinction may be clinically relevant when choosing between the two agents.

Gut Health Implications of the More Potent Drug

If tirzepatide produces more weight loss than semaglutide, it presumably produces more gastric emptying delay. The dual GLP-1 and GIP receptor agonism of tirzepatide adds GIP-mediated gastric motility effects on top of the GLP-1 component. Gastric half-emptying time studies confirm that tirzepatide produces comparable or slightly greater delay in gastric emptying compared to semaglutide at equivalent clinical doses. The migrating motor complex (MMC) — the interdigestive motility pattern that sweeps bacteria through the small intestine — is similarly impaired by both drugs, with tirzepatide's greater potency potentially translating to more pronounced MMC suppression.

This has direct implications for SIBO risk. A more potent motility-suppressing drug logically carries greater risk for small intestinal bacterial accumulation in susceptible patients. The SURMOUNT-5 trial did not assess SIBO as an outcome, and no trial in this space has done so systematically. But the mechanistic logic is straightforward: tirzepatide's superiority on weight loss comes with a corresponding degree of superiority on motility suppression, and patients with pre-existing gut motility vulnerabilities should weigh this more carefully when choosing between the two agents. Choosing the less potent option (semaglutide) for a patient with motility risk may be a reasonable clinical decision even if tirzepatide offers greater weight loss benefit.

What SURMOUNT-5 Means for Patients Choosing Between Drugs

For patients and clinicians weighing the choice between tirzepatide and semaglutide, SURMOUNT-5 provides important guidance — but context matters enormously. For patients who are primarily motivated by maximizing weight loss and have no significant gut motility concerns, the data clearly favors tirzepatide. The additional weight loss at 72 weeks is clinically meaningful, and the GI side effect profile is broadly similar, with tirzepatide potentially producing slightly less nausea despite greater potency.

For patients with pre-existing gut motility concerns — SIBO history, gastroparesis risk, constipation-predominant IBS, or prior gut surgery — the calculus is less straightforward. Semaglutide's somewhat lower motility-suppressing potency may represent a meaningful advantage for these patients, even if the absolute weight loss is less. Starting with semaglutide and escalating to tirzepatide if GI tolerance is good is a reasonable approach that has not been formally tested but aligns with the principle of starting the least potent effective treatment for sensitive populations. Insurance and cost considerations are also real factors: as of 2026, coverage for tirzepatide for weight management (Zepbound) remains more variable than for semaglutide (Wegovy) across payers.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.